OSTX Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to OS Therapies's net margin of --. OS Therapies's return on equity of -- beat CEL-SCI's return on equity of --.

OS Therapies has a consensus price target of $12.67, signalling upside risk potential of 151.7%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1843.54%. Given that CEL-SCI has higher upside potential than OS Therapies, analysts believe CEL-SCI is more attractive than OS Therapies.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. OS Therapies's net income of -$2.9M is higher than CEL-SCI's net income of -$6.9M. Notably, OS Therapies's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to OS Therapies's net margin of -416.75%. OS Therapies's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

OS Therapies has a consensus price target of $12.67, signalling upside risk potential of 151.7%. On the other hand IGC Pharma has an analysts' consensus of $3.63 which suggests that it could grow by 986.96%. Given that IGC Pharma has higher upside potential than OS Therapies, analysts believe IGC Pharma is more attractive than OS Therapies.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.462%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. OS Therapies's net income of -$2.9M is lower than IGC Pharma's net income of -$1.7M. Notably, OS Therapies's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus 20.18x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

MultiPlan has a net margin of -- compared to OS Therapies's net margin of -169.83%. OS Therapies's return on equity of -- beat MultiPlan's return on equity of -141.48%.

OS Therapies has a consensus price target of $12.67, signalling upside risk potential of 151.7%. On the other hand MultiPlan has an analysts' consensus of $10.00 which suggests that it could fall by -17.36%. Given that OS Therapies has higher upside potential than MultiPlan, analysts believe OS Therapies is more attractive than MultiPlan.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MultiPlan has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MultiPlan offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. MultiPlan pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than MultiPlan quarterly revenues of $230.5M. OS Therapies's net income of -$2.9M is higher than MultiPlan's net income of -$391.5M. Notably, OS Therapies's price-to-earnings ratio is -- while MultiPlan's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus 0.21x for MultiPlan. Usually stocks with elevated PS ratios are considered overvalued.

TScan Therapeutics has a net margin of -- compared to OS Therapies's net margin of -2849.09%. OS Therapies's return on equity of -- beat TScan Therapeutics's return on equity of -60.03%.

OS Therapies has a consensus price target of $12.67, signalling upside risk potential of 151.7%. On the other hand TScan Therapeutics has an analysts' consensus of $12.14 which suggests that it could grow by 303.42%. Given that TScan Therapeutics has higher upside potential than OS Therapies, analysts believe TScan Therapeutics is more attractive than OS Therapies.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison TScan Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TScan Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. TScan Therapeutics pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than TScan Therapeutics quarterly revenues of $1M. OS Therapies's net income of -$2.9M is higher than TScan Therapeutics's net income of -$29.9M. Notably, OS Therapies's price-to-earnings ratio is -- while TScan Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus 33.94x for TScan Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.